TheraRadar

Xenon

Pre-Approval PRO BETA
23
Total Trials
11
Phase 3
7
Phase 2
6
Recruiting
260
Score

Pipeline by Phase

Phase 3
11
Phase 2
7
Phase 1
8

Therapeutic Focus

Major Depressive Disorder Healthy Volunteers Focal Epilepsy Bipolar Depression Bipolar I Disorder

Clinical Trials (23)

NCT07076407 Phase 3 RECRUITING

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Started: 7/8/2025

NCT07172516 Phase 3 RECRUITING

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Started: 8/8/2025

NCT05716100 Phase 3 RECRUITING

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Started: 5/9/2023

NCT05667142 Phase 3 RECRUITING

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Started: 2/14/2023

NCT06775379 Phase 3 RECRUITING

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Started: 12/20/2024

NCT05718817 Phase 3 ENROLLING BY INVITATION

An Open-label Study of XEN1101 in Epilepsy

Started: 4/25/2023

NCT07217860 Phase 3 ENROLLING BY INVITATION

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

Started: 10/30/2025

NCT05614063 Phase 3 COMPLETED

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Started: 11/18/2022

NCT06922110 Phase 3 ENROLLING BY INVITATION

An Open-Label Study of Azetukalner in Major Depressive Disorder

Started: 3/18/2025

NCT04912856 Phase 3 TERMINATED

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Started: 8/17/2021

NCT04639310 Phase 3 TERMINATED

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Started: 3/29/2021

NCT03796962 Phase 2 ACTIVE NOT RECRUITING

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Started: 1/30/2019

NCT05376150 Phase 2 COMPLETED

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Started: 5/19/2022

NCT01195636 Phase 2 COMPLETED

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Started: 8/1/2010

NCT00954356 Phase 2 COMPLETED

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Started: 9/1/2009

NCT03340220 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Started: 11/13/2017

NCT04952467 Phase 1 COMPLETED

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

Started: 7/14/2021

NCT03467100 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

Started: 2/19/2018

NCT02656043 Phase 1 COMPLETED

A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

Started: 9/17/2015

NCT03468725 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

Started: 2/13/2018

NCT01486446 Phase 1 COMPLETED

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

Started: 12/1/2011

NCT01090622 Phase 1 COMPLETED

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Started: 4/1/2010

NCT00813670 Phase 1 COMPLETED

Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

Started: 11/1/2008

Drug Candidates

XEN1101 Azetukalner Placebo XEN496 XEN1101 10 mg XEN1101 20 mg XPF-008 Microcrystalline Cellulose XPF-010 Itraconazole 400mg
Activity Status: Active
Last Trial Started: 10/30/2025
Last Trial Ended: 2/3/2026
Trials (12 months): 3
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.